ContraFect Corporation (CFRX) News
Filter CFRX News Items
CFRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CFRX News Highlights
- CFRX's 30 day story count now stands at 3.
- Over the past 14 days, the trend for CFRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AMP, LI and UL are the most mentioned tickers in articles about CFRX.
Latest CFRX News From Around the Web
Below are the latest news stories about CONTRAFECT CORP that investors may wish to consider to help them evaluate CFRX as an investment opportunity.
ContraFect files for stock and warrants offering to raise $15MMore on Contrafect... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the workweek with a detailed breakdown of the biggest pre-market stock movers for Monday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! |
Why Is ContraFect (CFRX) Stock Up 23% Today?ContraFect stock is on the move Monday with heavy trading of CFRX as investors react to the latest clinical trial update from the FDA! |
Why Is Sigma Additive Solutions (SASI) Stock Down 27% Today?Sigma Additive Solutions stock is sliding lower on Monday as shares of SASI give up gains from an acquisition announcement on Friday! |
RAD Stock Sinks as Rite Aid Files for Ch. 11 BankruptcyRite Aid stock is taking a beating on Monday as investors in RAD react to the company filing for Chapter 11 bankruptcy protection. |
Why Is Nxu (NXU) Stock Down Today?Nxu stock is falling on Monday after the company reported insider selling of its shares as well as addressing a delisting notice. |
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trialYONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigation |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning! |
CFRX: IND Application for CF-370 Submitted to FDA…By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update IND Application for CF-370 Submitted to FDA On September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it had submitted an Investigational New Drug (IND) application to the U.S. FDA on September 15, 2023 for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated |